Brought to you by 
Keryx Biopharmaceuticals nets $65.7mm through FOPO
17 Feb 2021
Executive Summary
Renal therapeutics developer Keryx Biopharmaceuticals Inc. has netted $65.7mm through the follow-on public offering of 8.2mm common shares at $8.49. The company will use the money to build up its pre-launch/launch inventory and future commercialization of Phase III Zenerex, an oral ferric iron-based therapy which binds to phosphate in the GI tract to treat end-stage renal disease patients experiencing hyperphosphatemia.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Keryx Biopharmaceuticals nets $65.7mm through FOPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice